Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
71.95
-1.87 (-2.53%)
Mar 25, 2025, 4:00 PM EST - Market closed
Vaxcyte Employees
Vaxcyte had 414 employees as of December 31, 2024. The number of employees increased by 160 or 62.99% compared to the previous year.
Employees
414
Change (1Y)
160
Growth (1Y)
62.99%
Revenue / Employee
n/a
Profits / Employee
-$1,120,597
Market Cap
9.26B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 414 | 160 | 62.99% |
Dec 31, 2023 | 254 | 96 | 60.76% |
Dec 31, 2022 | 158 | 69 | 77.53% |
Dec 31, 2021 | 89 | 31 | 53.45% |
Dec 31, 2020 | 58 | 15 | 34.88% |
Dec 31, 2019 | 43 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PCVX News
- 4 weeks ago - Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewsWire
- 6 weeks ago - Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - GlobeNewsWire
- 7 weeks ago - Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 7 weeks ago - Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - GlobeNewsWire
- 2 months ago - Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy - Seeking Alpha
- 4 months ago - Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - GlobeNewsWire